1 active not recruiting, 1 completed, 1 recruiting. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
Follow Breast: new trials by email Literature Review of Breast trials Research Report on Breast
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) Capecitabine, Sarilumab 150mg or 200 mg plus Capecitabine, Sarilumab 150mg plus Capecitabine - Breast, Metastatic | Phase 1 / Phase 2 | Recruiting | University of Southern California | 65 | 2020-09-26 | 2026-03-10 |
| A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. Olaparib, MEDI4736, Bevacizumab - Ovarian, Breast | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 264 | 2016-03-17 | 2026-07-14 |
| Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer Carboplatin, Capecitabine, Vinorelbine - Breast, Cancer | Phase 1 / Phase 2 | Completed | University of New Mexico | 33 | 2000-05-01 | 2010-01-07 |
Neoplasms (2) · Breast Neoplasms (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Small Cell Lung Carcinoma (1) · Stomach Neoplasms (1)
Adnexal Diseases (1) · Breast Diseases (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1)
Bevacizumab (1) · Capecitabine (1) · Carboplatin (1) · Vinorelbine (1) · durvalumab (1) · olaparib (1) · sarilumab (1)
AstraZeneca (1) · University of New Mexico (1) · University of Southern California (1)
United States (3) · France (1) · Israel (1) · Netherlands (1) · South Korea (1) · Switzerland (1) · United Kingdom (1)
Anastasia Martynova, MD (1) · Ian Rabinowitz, MD (1) · Susan Domchek, MD (1)
PMID 32771088, PMID 35756843, PMID 37939124
2015 (1), R01CA238387 (1)